Open Access Open Access  Restricted Access Subscription Access

Exploring Drug Therapies for Lymphoma: A Comprehensive Overview

Muralinath E., Arun Kumar Sharma, Ramesh Padodara D., Vivek Kumar Singh, Arjun Bodedara, Kalyan C., Guruprasad M., Amrita Vasava

Abstract


A particular kind of cancer called lymphoma develops in the lymphatic system, which is an essential component of the immune system. Chemotherapy is very useful in the treatment of lymphoma. These medications work by specifically targeting and quickly eliminating cancer cells in addition to dividing cells. Cyclophosphamide and doxorubicin are common chemotherapy medications for lymphoma. Prednisone and vincristine collectively termed as CHOP. While effective, chemotherapy can cause side effects because of its impact on health cells. Mono clonal antibodies generally show revolutionized lymphoma treatment by particularly targeting proteins on the surface of cancer cells. Rituximab, for instance, targets the CD 20 protein observed on B_ cell lymphoma. This antibody heps the immune system in recognizing and attacking cancer cells, resulting in an improved outcomes, especially in combination with chemotherapy. Novel drugs designed to target particular molecules participated in cancer growth have emerged as a promising avenue fir lymphoma treatment. Ibrutinib and idealistic, for example, stop signaling pathways critical fir B_ cell lymphoma survival. Compared to conventional chemotherapy, these tailored medicines may have fewer adverse effects because of their more focused approach. The body's immune system is specifically strengthened by immunotherapy to combat cancer. Check point inhibitors namely pembrolizumab and novolumab are being explored especially in the context of lymphoma treatment. These drugs release the brakes on the immune system, permitting it to recognize and attack cancer cells. Immuno therapy is demonstrating promise especially in refractory cases and as a maintenance strategy. Protease inhibitors namely bortezomib interfere with the breakdown of proteins particularly veithin cancer cells, resulting in cell death. While initially developed for multiple myeloma, these agents have dominated efficacy in certain subtypes of lymphoma making them a valuable addition to treat options. Finally it is concluded that the treatment landscape for lymphoma is continually evolving, with a growing arsenal of drugs offering hope for enhanced outcomes.


Full Text:

PDF

References


Mugnaini, E. N., & Ghosh, N. (2016). Lymphoma. Primary Care: Clinics in Office Practice, 43(4), 661-675.

Matasar, M. J., & Zelenetz, A. D. (2008). Overview of lymphoma diagnosis and management. Radiologic Clinics of North America, 46(2), 175-198.

Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J. S., ... & Melbye, M. (2003). Characteristics of Hodgkin's lymphoma after infectious mononucleosis. New England Journal of Medicine, 349(14), 1324-1332.

Said, W., Chien, K., Takeuchi, S., Tasaka, T., Asou, H., Cho, S. K., ... & Koeffler, H. P. (1996). Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells.

Biggar, R. J., Jaffe, E. S., Goedert, J. J., Chaturvedi, A., Pfeiffer, R., Engels, E. A., & HIV/AIDS Cancer Match Study. (2006). Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood, 108(12), 3786-3791.

Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., ... & Yunus, F. (2010). Non-Hodgkin’s lymphomas. Journal of the National Comprehensive Cancer Network, 8(3), 288-334.

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., ... & Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, The Journal of the American Society of Hematology, 127(20), 2375-2390.

Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012). Non-hodgkin lymphoma. The Lancet, 380(9844), 848-857.

Mauch, P. M., Kalish, L. A., Kadin, M., Coleman, C. N., Osteen, R., & Hellman, S. (1993). Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer, 71(6), 2062-2071.

Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J., Amess, J., ... & Lister, T. A. (2007). Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. Journal of Clinical Oncology, 25(17), 2426-2433.

Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., ... & Bates, S. E. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, The Journal of the American Society of Hematology, 117(22), 5827-5834.

Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A., Zhuang, H., ... & Schuster, S. J. (2003). Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, The Journal of the American Society of Hematology, 101(10), 3875-3876.

Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., ... & Savage, K. J. (2016). CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology, 34(26), 3150-3156.

Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., ... & Brugger, W. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet, 381(9873), 1203-1210.

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., ... & Radford, J. (2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. New England Journal of Medicine, 378(4), 331-344.

Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., ... & Barrington, S. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. New England Journal of Medicine, 372(17), 1598-1607.

Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., ... & Loeffler, M. (2003). Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348(24), 2386-2395.

Linch, D., Goldstone, A. H., McMillan, A., Chopra, R., Hudson, G. V., Winfield, D., ... & Milligan, D. (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. The Lancet, 341(8852), 1051-1054.

Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., ... & Tilly, H. (2010). Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, The Journal of the American Society of Hematology, 116(12), 2040-2045.

Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., ... & Miller, T. P. (2008). Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of clinical oncology, 26(14), 2258-2263.

Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., ... & Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346(4), 235-242.

Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., ... & Oki, Y. (2014). Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet Oncology, 15(9), 1019-1026.

Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., ... & Staudt, L. M. (2015). Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature medicine, 21(8), 922-926.

Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., ... & Chauvin, F. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333(23), 1540-1545.

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., ... & Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531-2544.

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., ... & Maziarz, R. T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45-56.

Horning, S. J., & Rosenberg, S. A. (1984). The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine, 311(23), 1471-1475.

Flinn, I. W., Van Der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., ... & Burke, J. M. (2019). First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology, 37(12), 984.

Bachy, E., Seymour, J. F., Feugier, P., Offner, F., López-Guillermo, A., Belada, D., ... & Salles, G. (2019). Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. Journal of Clinical Oncology, 37(31), 2815.

Thomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., ... & Kantarjian, H. (2006). Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia. Cancer, 106(7), 1569-1580.

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., ... & Shustov, A. (2015). Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. Journal of Clinical Oncology, 33(23), 2492.

Göknar, N., Çakır, E., Çakır, F.B., Kasapcopur, O., Yegen, G., Gedik, A.H., Oktem, F. (2015). A Difficult Case of Hodgkin Lymphoma with Differential Diagnosis of Tuberculosis and Sarcoidosis. Hematol Rep., 7(2), 5644.

Mikhaeel, N. G., Milgrom, S. A., Terezakis, S., Berthelsen, A. K., Hodgson, D., Eich, H. T., ... & Specht, L. (2019). The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology* Biology* Physics, 104(3), 501-512.

Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010). Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of clinical oncology, 28(14), 2373-2380.

International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993). A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329(14), 987-994.


Refbacks

  • There are currently no refbacks.